vs
Amphastar Pharmaceuticals, Inc.（AMPH）とEverCommerce Inc.（EVCM）の財務データ比較。上の社名をクリックして会社を切り替えられます
Amphastar Pharmaceuticals, Inc.の直近四半期売上が大きい（$183.1M vs $151.2M、EverCommerce Inc.の約1.2倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs 4.0%、差は9.3%）。EverCommerce Inc.の前年同期比売上増加率が高い（5.2% vs -1.8%）。Amphastar Pharmaceuticals, Inc.の直近四半期フリーキャッシュフローが多い（$24.6M vs $21.0M）。過去8四半期でEverCommerce Inc.の売上複合成長率が高い（4.7% vs 3.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
EverCommerce Inc.は中小サービス業企業向け統合SaaSソリューションの大手プロバイダーで、主に北米及び一部のグローバル市場で事業を展開しています。業務管理、決済処理、顧客エンゲージメント、マーケティングツールを提供し、宅内サービス、ヘルスケア、フィットネスなどを主要顧客層としています。
AMPH vs EVCM — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $151.2M |
| 純利益 | $24.4M | $6.0M |
| 粗利率 | 46.8% | — |
| 営業利益率 | 19.4% | 8.8% |
| 純利益率 | 13.3% | 4.0% |
| 売上前年比 | -1.8% | 5.2% |
| 純利益前年比 | -35.7% | 149.4% |
| EPS（希薄化後） | $0.51 | $0.04 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $151.2M | ||
| Q3 25 | $191.8M | $147.5M | ||
| Q2 25 | $174.4M | $148.0M | ||
| Q1 25 | $170.5M | $142.3M | ||
| Q4 24 | $186.5M | $143.7M | ||
| Q3 24 | $191.2M | $140.1M | ||
| Q2 24 | $182.4M | $140.5M | ||
| Q1 24 | $171.8M | $137.9M |
| Q4 25 | $24.4M | $6.0M | ||
| Q3 25 | $17.4M | $11.1M | ||
| Q2 25 | $31.0M | $8.2M | ||
| Q1 25 | $25.3M | $-7.7M | ||
| Q4 24 | $38.0M | $-12.2M | ||
| Q3 24 | $40.4M | $-9.2M | ||
| Q2 24 | $37.9M | $-3.4M | ||
| Q1 24 | $43.2M | $-16.3M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 8.8% | ||
| Q3 25 | 13.2% | 10.8% | ||
| Q2 25 | 24.2% | 10.7% | ||
| Q1 25 | 21.9% | 10.0% | ||
| Q4 24 | 24.2% | 8.8% | ||
| Q3 24 | 29.8% | 7.2% | ||
| Q2 24 | 30.3% | 5.5% | ||
| Q1 24 | 27.9% | -3.1% |
| Q4 25 | 13.3% | 4.0% | ||
| Q3 25 | 9.0% | 7.5% | ||
| Q2 25 | 17.8% | 5.5% | ||
| Q1 25 | 14.8% | -5.4% | ||
| Q4 24 | 20.4% | -8.5% | ||
| Q3 24 | 21.1% | -6.5% | ||
| Q2 24 | 20.8% | -2.4% | ||
| Q1 24 | 25.1% | -11.8% |
| Q4 25 | $0.51 | $0.04 | ||
| Q3 25 | $0.37 | $0.06 | ||
| Q2 25 | $0.64 | $0.04 | ||
| Q1 25 | $0.51 | $-0.04 | ||
| Q4 24 | $0.74 | $-0.06 | ||
| Q3 24 | $0.78 | $-0.05 | ||
| Q2 24 | $0.73 | $-0.02 | ||
| Q1 24 | $0.81 | $-0.09 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $129.7M |
| 総負債低いほど良い | $608.7M | $523.4M |
| 株主資本純資産 | $788.8M | $716.9M |
| 総資産 | $1.6B | $1.4B |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | 0.73× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $129.7M | ||
| Q3 25 | $276.2M | $106.9M | ||
| Q2 25 | $231.8M | $151.1M | ||
| Q1 25 | $236.9M | $148.4M | ||
| Q4 24 | $221.6M | $135.8M | ||
| Q3 24 | $250.5M | $101.6M | ||
| Q2 24 | $217.8M | $86.7M | ||
| Q1 24 | $289.6M | $90.0M |
| Q4 25 | $608.7M | $523.4M | ||
| Q3 25 | $608.6M | $524.6M | ||
| Q2 25 | $607.7M | $525.8M | ||
| Q1 25 | $603.9M | $526.9M | ||
| Q4 24 | $601.6M | $527.9M | ||
| Q3 24 | $596.4M | $529.0M | ||
| Q2 24 | $586.9M | $530.1M | ||
| Q1 24 | $594.0M | $531.1M |
| Q4 25 | $788.8M | $716.9M | ||
| Q3 25 | $776.7M | $728.5M | ||
| Q2 25 | $757.5M | $744.0M | ||
| Q1 25 | $751.3M | $739.6M | ||
| Q4 24 | $732.3M | $750.8M | ||
| Q3 24 | $727.7M | $770.7M | ||
| Q2 24 | $713.3M | $784.1M | ||
| Q1 24 | $672.4M | $800.7M |
| Q4 25 | $1.6B | $1.4B | ||
| Q3 25 | $1.7B | $1.4B | ||
| Q2 25 | $1.6B | $1.4B | ||
| Q1 25 | $1.6B | $1.4B | ||
| Q4 24 | $1.6B | $1.4B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.5B | $1.5B | ||
| Q1 24 | $1.6B | $1.5B |
| Q4 25 | 0.77× | 0.73× | ||
| Q3 25 | 0.78× | 0.72× | ||
| Q2 25 | 0.80× | 0.71× | ||
| Q1 25 | 0.80× | 0.71× | ||
| Q4 24 | 0.82× | 0.70× | ||
| Q3 24 | 0.82× | 0.69× | ||
| Q2 24 | 0.82× | 0.68× | ||
| Q1 24 | 0.88× | 0.66× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $21.3M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $21.0M |
| FCFマージンFCF / 売上 | 13.4% | 13.9% |
| 設備投資強度設備投資 / 売上 | 4.5% | 0.2% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | 3.52× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $109.2M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $21.3M | ||
| Q3 25 | $52.6M | $32.5M | ||
| Q2 25 | $35.6M | $27.0M | ||
| Q1 25 | $35.1M | $30.7M | ||
| Q4 24 | $29.0M | $48.4M | ||
| Q3 24 | $60.0M | $27.5M | ||
| Q2 24 | $69.1M | $23.9M | ||
| Q1 24 | $55.3M | $13.3M |
| Q4 25 | $24.6M | $21.0M | ||
| Q3 25 | $47.2M | $31.6M | ||
| Q2 25 | $25.0M | $26.5M | ||
| Q1 25 | $24.4M | $30.2M | ||
| Q4 24 | $16.6M | $48.2M | ||
| Q3 24 | $46.2M | $27.4M | ||
| Q2 24 | $63.1M | $23.3M | ||
| Q1 24 | $46.5M | $12.9M |
| Q4 25 | 13.4% | 13.9% | ||
| Q3 25 | 24.6% | 21.4% | ||
| Q2 25 | 14.3% | 17.9% | ||
| Q1 25 | 14.3% | 21.2% | ||
| Q4 24 | 8.9% | 33.5% | ||
| Q3 24 | 24.1% | 19.5% | ||
| Q2 24 | 34.6% | 16.6% | ||
| Q1 24 | 27.1% | 9.4% |
| Q4 25 | 4.5% | 0.2% | ||
| Q3 25 | 2.8% | 0.6% | ||
| Q2 25 | 6.1% | 0.3% | ||
| Q1 25 | 6.3% | 0.3% | ||
| Q4 24 | 6.7% | 0.2% | ||
| Q3 24 | 7.2% | 0.1% | ||
| Q2 24 | 3.3% | 0.5% | ||
| Q1 24 | 5.1% | 0.3% |
| Q4 25 | 1.35× | 3.52× | ||
| Q3 25 | 3.03× | 2.93× | ||
| Q2 25 | 1.15× | 3.31× | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
EVCM
| Transferred Over Time | $146.4M | 97% |
| Transferred At Point In Time | $4.8M | 3% |
